KTTA Stock Analysis: Buy, Sell, or Hold?
KTTA - Pasithea Therapeutics Corp. Common Stock
$0.54
0.07 (14.77%)
▲
5d:
+12.26%
30d:
+12.33%
90d:
-25.19%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When KTTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: KTTA is 10.1% above its trading range ($0.49). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: KTTA is 10.1% above its trading range ($0.49). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: KTTA is currently trading at $0.54, which is considered extended relative to its 30-day fair value range of $0.45 to $0.49.
Technical Outlook: Technically, KTTA is in a strong downtrend. The price is approaching resistance at $0.54. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.8% recently.
Market Sentiment: KTTA scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.00 (+456.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KTTA is in a strong downtrend. The price is approaching resistance at $0.54. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.8% recently.
Market Sentiment: KTTA scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.00 (+456.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.45 -
$0.49
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+10.1% above its trading range)
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+14.8%)
- BULLISH: Trading 456.2% below Wall St target ($3.00)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.45 -
$0.49
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.44
Resistance Level
$0.54
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.17
Wall Street Target
$3.00
(+456.2%)
Revenue Growth (YoY)
1498.1%
Share & Embed Analysis
Last updated: August 22, 2026 9:01 PM ET
Data refreshes hourly during market hours. Next update: 10:01 PM
Data refreshes hourly during market hours. Next update: 10:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KTTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
